구조모아 (StructureMoa)항암 chemical structure spider web
방문autologous CD19-directed chimeric antigen receptor (CAR) T-cells(AstraZeneca)은 CD19 표적 세포·유전자 치료로, Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 77.3% (ClinicalTrials.gov NCT03642626). 차별점: novel anti-inflammatory CAR-Microglia (CAR-Mic) incorporating a construct based on the TAM receptor family (TYRO3, AXL, and M.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
CD19
Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL
Recruiting
2026-09-02
Data Confidence · Medium
Development Signal · Emerging
CAR T-cell product type, and higher day 0 C-reactive protein were
AAV) but is clinically still in an early developmental stage
humanized mouse models of triple-negative breast cancer, including postoperative recurrence and lung metastas
novel anti-inflammatory CAR-Microglia (CAR-Mic) incorporating a construct based on the TAM receptor family (TYRO3, AXL, and M
CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI
t cellular production also enable a deep B‑cell or plasma cell depletion via T cell-mediated cytotoxicity
apoptosis, activation of endoplasmic reticulum stress pathways, and inhibition of tumor invasiveness
biomarkers such as body composition metrics
downregulation, stromal barricades, and T-cell exhaustion, rendering conventional immunotherapies ineffective in "cold" lesions
구조화 데이터
ration of humanized patient-derived xenograft
dogs
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
autologous CD19-directed chimeric antigen receptor (CAR) T-cells(AstraZeneca)은 CD19 표적 세포·유전자 치료로, Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 77.3% (ClinicalTrials.gov NCT03642626). 차별점: novel anti-inflammatory CAR-Microglia (CAR-Mic) incorporating a construct based on the TAM receptor family (TYRO3, AXL, and M.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
CD19
Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL
Recruiting
2026-09-02
Data Confidence · Medium
Development Signal · Emerging
CAR T-cell product type, and higher day 0 C-reactive protein were
AAV) but is clinically still in an early developmental stage
humanized mouse models of triple-negative breast cancer, including postoperative recurrence and lung metastas
novel anti-inflammatory CAR-Microglia (CAR-Mic) incorporating a construct based on the TAM receptor family (TYRO3, AXL, and M
CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI
t cellular production also enable a deep B‑cell or plasma cell depletion via T cell-mediated cytotoxicity
apoptosis, activation of endoplasmic reticulum stress pathways, and inhibition of tumor invasiveness
biomarkers such as body composition metrics
downregulation, stromal barricades, and T-cell exhaustion, rendering conventional immunotherapies ineffective in "cold" lesions
구조화 데이터
ration of humanized patient-derived xenograft
dogs
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.